

DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

POLICY: Cabergoline Drug Quantity Management Policy – Per Days

- Cabergoline tablets – generic only

REVIEW DATE: 06/01/2022

OVERVIEW

Cabergoline tablets are indicated for the treatment of **hyperprolactinemic disorders**, either idiopathic or due to pituitary adenomas.¹

Cabergoline has also been used off-label for the management of acromegaly, Parkinson’s disease, and Cushing’s syndrome.²⁻⁸

Dosing

The recommended dose of cabergoline for hyperprolactinemic disorder is 0.25 mg twice weekly.¹ The dose may be increased by 0.25 mg twice weekly up to a maximum dose of 1 mg twice weekly (4 x 0.5 mg tablets/week). Dose adjustments should not occur more frequently than every 4 weeks. Some patients have required doses up to 11 mg/week to overcome resistance.²

For acromegaly, cabergoline has been used at doses ranging from 0.3 mg/week to 7 mg/week.^{3,4} For Parkinson’s disease, cabergoline has been used at doses up to 6 mg/day (mean doses ranging from 2.8 mg/day to 3 mg/day).⁵ For restless leg syndrome, cabergoline has been used at doses of up to 3 mg/day.^{6,8} For Cushing’s syndrome, cabergoline has been used at doses up to 7 mg/week.⁷

Availability

Cabergoline is available as 0.5 mg scored tablets in bottles containing 8 tablets.¹

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of cabergoline. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Automation: None.

Drug Quantity Limits

Product	Strength and Form	Maximum Quantity per 28 Days
Cabergoline tablets	0.5 mg tablets	8 tablets*

* 8 tablets provide adequate quantity of medication for 4 weeks of therapy at a dose of 0.5 mg twice weekly.

CRITERIA

1. If the patient has hyperprolactinemia, approve the requested quantity not to exceed 88 tablets per 28-day supply.
Note: Some patients may require doses up to 11 mg/week to overcome resistance.²
2. If the patient has acromegaly, approve the requested quantity per 28-day supply.
3. If the patient has Parkinson’s disease, approve the requested quantity per 28-day supply.
4. If the patient has restless legs syndrome, approve the requested quantity per 28-day supply.
5. If the patient has Cushing’s syndrome, approve the requested quantity per 28-day supply.

REFERENCES

1. Cabergoline tablets [prescribing information]. Peapack, NJ: Greenstone; November 2019.
2. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011;96(2):273–288. Available at: <https://www.endocrine.org/clinical-practice-guidelines/hyperprolactinemia>. Accessed on May 23, 2022.
3. Katznelson L, Laws ER, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011;99(11):2933–3951. Available at: <https://www.endocrine.org/clinical-practice-guidelines/acromegaly> <https://academic.oup.com/jcem/article/99/11/3933/2836347>. Accessed on May 23, 2022.
4. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. *J Clin Endocrinol Metab.* 2011;96(5):1327-1335.
5. Pringsheim T, Day GS, Smith DB, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline. A report of the American Academy of Neurology subcommittee. Available at: <https://www.aan.com/Guidelines/home/GuidelineDetail/1043>. Accessed on May 23, 2022.
6. Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults - an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses. *Sleep* 2012;35(8):1039-1062. Available at <http://www.aasmnet.org/Resources/PracticeParameters/TreatmentRLS.pdf>. Accessed May 23, 2022.
7. L. Niemen, B. Biller, J. Findling, et al. Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2015;100(8):2807–2831. Available at <https://academic.oup.com/jcem/article/100/8/2807/2836065>. Accessed May 24, 2022.
8. Winkelman JW, Armstrong M, Allen RP, et al. Practice guideline summary: treatment of restless leg syndrome in adults. Report on of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. *Neurology.* 2016;87:2585-2593.